Outset reaffirmed its previously provided guidance for 2024 including revenue of $145 million to $153 million, growing 12% to 18% over 2023, and non-GAAP gross margin in the low-30% range for the full year 2024, exiting the year in the mid-30% range for the fourth quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical says FDA grants 510(k) clearance of TabloCart with prefiltration
- Stifel says Outset TabloCart with Prefiltration approval earlier than expected
- FDA posts 510(k) approval of Outset Medical’s TabloCart
- Outset Medical U.S. Renal Care in deal to expand U.S. home dialysis
- Outset Medical initiated with a Buy at BTIG
Questions or Comments about the article? Write to editor@tipranks.com